ABT
Abbott Laboratories
Set alert
- YTD
- -15.24%
- 1 year
- -14.82%
- Open
- 106.15
- Prev close
- 104.57
- Mkt cap
- 184.98B
- Vol
- 8.44M
- Avg vol
- 8.76M
- EPS
- 2.69
- P/E
- 39.48
- Div yield
- 2.41%
More statistics
- Low
- 104.60
- High
- 106.85
- Forward P/E
- 17.89
- Beta
- 0.58
- Short ratio
- 1.84
- Inst. own
- 81.90%
- Dividend
- 2.52
- Ex-div date
- Oct 14, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 104.50
- 200-d avg
- 101.79
- 1y target
- 118.52
Key statistics
- Market cap
- 185.05B
- Enterprise value
- 208.72B
- Trailing P/E
- 39.49
- Forward P/E
- 17.89
- PEG ratio
- 1.49
- Price / sales
- 3.84
- Price / book
- 3.60
- EPS (TTM)
- 2.69
- Beta
- 0.58
- Dividend yield
- 2.41%
- Payout ratio
- 78.71%
- Profit margin
- 9.75%
- Revenue (TTM)
- 48.23B
- Revenue growth
- 14.50%
- Free cash flow
- 0
- Total cash
- 5.60B
- Total debt
- 32.72B
- Return on equity
- 0.00%
- Shares outstanding
- 1.74B
- Short % of float
- 1.12%
- 50-day average
- 104.50
- 200-day average
- 101.79
Analyst view
Consensus: buy
- Target (low)
- 100.00
- Target (mean)
- 118.52
- Target (high)
- 130.00
- Strong buy5
- Buy18
- Hold5
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 1.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 1.64 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 1.42 | 1.42 | 0.00 | 0.00% |
| Jul 16, 2026 | Jun 30, 2026 | 1.28 | 1.31 | +0.03 | +2.34% |
| Apr 16, 2026 | Mar 31, 2026 | 1.14 | 1.15 | +0.01 | +0.88% |
| Jan 22, 2026 | Dec 31, 2025 | 1.50 | 1.50 | 0.00 | 0.00% |
| Oct 15, 2025 | Sep 30, 2025 | 1.30 | 1.30 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Argus Research | down | Buy | Hold |
| Oct 23, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 22, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | JP Morgan | main | Overweight | Overweight |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- abbott.com
News
- 2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution
- Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Best Dividend Aristocrats For November 2026
- U.S. politician makes super suspicious Big Tech stock trades
- Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
- Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
- Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
- Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead
- This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Your note
Sign in to keep a note on ABT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN HUBERT L. | Officer | Stock Award(Grant) | Feb 24, 2025 | 200,281 |
| BOUDREAU PHILIP P | Chief Financial Officer | Purchase | Apr 22, 2026 | 0 |
| CONROY KEVIN T | Director | Stock Award(Grant) | Apr 23, 2026 | 133,737 |
| EARNHARDT LISA D | Officer | Stock Award(Grant) | Feb 23, 2026 | 98,984 |
| FORD ROBERT B. | Chief Executive Officer | Sale | Aug 24, 2026 | 522,664 |
| MORELAND MARY K | Officer | Sale | Mar 1, 2026 | 116,136 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.82% | 152,563,476 | 16.21B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.57% | 113,750,994 | 12.08B | Jun 29, 2026 |
| State Street Corporation | 4.68% | 80,926,234 | 8.60B | Jun 29, 2026 |
| Charles Schwab Investment Management, Inc. | 3.45% | 59,674,507 | 6.34B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.83% | 49,017,866 | 5.21B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.27% | 39,219,337 | 4.17B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.20% | 55,297,279 | 5.87B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.75% | 47,631,745 | 5.06B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 45,138,490 | 4.80B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 23,056,907 | 2.45B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.31% | 22,610,290 | 2.40B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 21,408,918 | 2.27B | Sep 29, 2026 |